Clover Health Investments (CLOV) CEO Toy Sells $291K of Stock
Key Points
- Chief Executive Officer Andrew Toy sold 62,176 shares of Clover Health Investments, Corp. on October 15, 2026, at a price of $4.68 per share for a total value of about $290,983.68.
- The planned sale was executed under a pre-arranged Rule 10b5-1 trading plan, reducing the executive's holdings by roughly 0.68% to 9,078,334 shares.
- The stock recently traded around $4.44 as of October 19, 2026, sitting below its 50-day moving average but well above its 200-day trend line ahead of November earnings.
Since the trade, $CLOV is down 5.1% to date (from the $4.68 close on Oct 15, 2026).
Get Clover Health Investments, Corp. text alerts
We text you when insiders, Congress, analysts or big funds move on $CLOV.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Clover Health Investments, Corp. alert may contain errors. Disclosures
Clover Health Investments, Corp. Chief Executive Officer Andrew Toy sold 62,176 shares of company stock on October 15, 2026. According to a Form 4 filed with the Securities and Exchange Commission, the transaction took place at a price of $4.68 per share, bringing the total value of the sale to about $290,983.68.
CLOV
Clover Health Investments, Corp.
Inside Andrew Toy's Clover Health Trade
The planned sale was executed under a pre-arranged Rule 10b5-1 trading plan. The trade reduced the executive's direct holdings by about 0.68%, leaving him with 9,078,334 shares of common stock following the transaction.
Other Institutional Activity in Clover Health Investments, Corp.
Large institutional funds continue adjusting their positions in the healthcare firm. Nuveen, LLC grew its holdings by 5,356,158 shares, ending with 6,291,699 shares worth about $27,935,143. Meanwhile, PNC Financial Services Group, Inc. trimmed its stake, selling 200,251 shares to finish with 3,563,874 shares valued at roughly $15,823,600.
Clover Health Investments, Corp. Stock Down 7.3%
The stock recently traded around $4.44 as of October 19, 2026, down about 5.1% from its close of $4.68 on the day of the executive's trade. Shares sit slightly below the 50-day moving average of $4.46, yet remain well above the 200-day average of $3.42. The recent price is down about 20.6% from its 52-week high of $5.59 while staying 181.0% above its 52-week low of $1.58.
Recent Earnings
The healthcare provider reported trailing twelve-month revenue of $2.48 billion alongside a basic earnings per share of negative $0.05. Profitability metrics show a net profit margin of negative 0.7% and a return on equity of negative 5.1%. The company is scheduled to release its next financial results on November 4, 2026.
Insider Buying and Selling at Clover Health Investments, Corp.
Prior insider activity included multiple planned sales by company executives earlier in the year, such as transactions by Medicare Advantage CEO Jamie Reynoso and Chief Legal Officer Karen Soares.
Analysts Set New Price Targets
Wall Street firms maintain varied stances on the stock, with Canaccord Genuity carrying a Buy rating and UBS maintaining a Neutral view.
About Clover Health Investments, Corp.
Based in Wilmington, Delaware, Clover Health Investments operates as a healthcare company that provides Medicare Advantage plans, including preferred provider organization and health maintenance organization options. The firm also develops the Clover Assistant software platform to help physicians manage chronic conditions.
Bottom Line
Investors will watch the upcoming earnings release on November 4, 2026, for further updates on financial performance. Insider transactions under pre-arranged plans remain a routine part of executive compensation and portfolio management.
Related Filing Alerts
Source: Andrew Toy's Form 4 filing on $CLOV (Oct 15, 2026). Written by software, not financial advice. How we make alerts